Respiratory Syncytial Virus (RSV) Therapeutics Market to Grow at CAGR of 13 % through 2031 Owing to Rising Prevalence of ...
The Respiratory Syncytial Virus (RSV) Therapeutics Market is valued at USD 5.75 Billion in 2023 and is expected to reach a valuation of USD 15.28 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 13% from 2024 to 2031. Respiratory …